Lawrence E. Feldman, MD

Lawrence E. Feldman, MD, discusses the phase 3 LEAP-006 trial evaluating lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Lawrence E. Feldman, MD, discusses utilizing prophylactic cranial irradiation in limited-stage and extensive-stage small cell lung cancer.

Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses the future of durvalumab (Imfinzi) and tremelimumab in non–small cell lung cancer (NSCLC).

Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.